当前位置: X-MOL 学术J. Clin. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study
Journal of Clinical Oncology ( IF 42.1 ) Pub Date : 2020-01-01 , DOI: 10.1200/jco.19.01056
Michael S Khodadoust 1 , Alain H Rook 2 , Pierluigi Porcu 3 , Francine Foss 4 , Alison J Moskowitz 5 , Andrei Shustov 6 , Satish Shanbhag 7 , Lubomir Sokol 8 , Steven P Fling 9 , Nirasha Ramchurren 9 , Robert Pierce 9 , Asa Davis 9 , Richard Shine 9 , Shufeng Li 1 , Sophia Fong 1 , Jinah Kim 1 , Yi Yang 9 , Wendy M Blumenschein 10 , Jennifer H Yearley 10 , Biswajit Das 11 , Rajesh Patidar 11 , Vivekananda Datta 11 , Erin Cantu 11 , Justine N McCutcheon 11 , Chris Karlovich 11 , P Mickey Williams 11 , Priyanka B Subrahmanyam 1 , Holden T Maecker 1 , Steven M Horwitz 5 , Elad Sharon 12 , Holbrook E Kohrt 1 , Martin A Cheever 9 , Youn H Kim 1
Affiliation  

PURPOSE To assess the efficacy of pembrolizumab in patients with advanced relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS). PATIENTS AND METHODS CITN-10 is a single-arm, multicenter phase II trial of 24 patients with advanced MF or SS. Patients were treated with pembrolizumab 2 mg/kg every 3 weeks for up to 24 months. The primary end point was overall response rate by consensus global response criteria. RESULTS Patients had advanced-stage disease (23 of 24 with stage IIB to IV MF/SS) and were heavily pretreated with a median of four prior systemic therapies. The overall response rate was 38% with two complete responses and seven partial responses. Of the nine responding patients, six had 90% or more improvement in skin disease by modified Severity Weighted Assessment Tool, and eight had ongoing responses at last follow-up. The median duration of response was not reached, with a median response follow-up time of 58 weeks. Immune-related adverse events led to treatment discontinuation in four patients. A transient worsening of erythroderma and pruritus occurred in 53% of patients with SS. This cutaneous flare reaction did not result in treatment discontinuation for any patient. The flare reaction correlated with high PD-1 expression on Sézary cells but did not associate with subsequent clinical responses or lack of response. Treatment responses did not correlate with expression of PD-L1, total mutation burden, or an interferon-γ gene expression signature. CONCLUSION Pembrolizumab demonstrated significant antitumor activity with durable responses and a favorable safety profile in patients with advanced MF/SS.

中文翻译:


派姆单抗治疗复发性和难治性蕈样肉芽肿和塞扎里综合征:一项多中心 II 期研究



目的 评估派姆单抗对晚期复发或难治性蕈样肉芽肿 (MF) 或塞扎里综合征 (SS) 患者的疗效。患者和方法 CITN-10 是一项单组、多中心 II 期试验,受试者为 24 名晚期 MF 或 SS 患者。患者每 3 周接受 2 mg/kg 派姆单抗治疗,治疗时间长达 24 个月。主要终点是根据全球共识缓解标准得出的总体缓解率。结果 患者患有晚期疾病(24 名患者中的 23 名患者为 IIB 至 IV 期 MF/SS),并且接受了中位数为 4 次的先前全身治疗的大量预处理。总体答复率为 38%,其中有 2 名完全答复和 7 名部分答复。在九名有反应的患者中,通过修改后的严重程度加权评估工具,六名患者的皮肤病改善了 90% 或更多,八名患者在最后一次随访中持续有反应。中位缓解持续时间尚未达到,中位缓解随访时间为 58 周。免疫相关不良事件导致四名患者停止治疗。 53% 的 SS 患者出现短暂性红皮病和瘙痒恶化。这种皮肤耀斑反应并未导致任何患者停止治疗。耀斑反应与 Sézary 细胞上的高 PD-1 表达相关,但与随后的临床反应或缺乏反应无关。治疗反应与 PD-L1 表达、总突变负荷或干扰素-γ 基因表达特征无关。结论 Pembrolizumab 在晚期 MF/SS 患者中表现出显着的抗肿瘤活性、持久的反应和良好的安全性。
更新日期:2020-01-01
down
wechat
bug